Strategic Collaboration Potential partnership with larger medical organizations and foundations focused on muscular dystrophy research and treatment development, leveraging Hunterian Medicine's CRISPR delivery tech to expand clinical applications and access new funding streams.

Niche Market Position Target rare genetic disease programs (Duchenne and Becker muscular dystrophy) where a novel 2-for-1 AAV CRISPR delivery could provide a competitive edge, aligning with sponsors seeking differentiated gene-editing approaches.

Funding Trajectory capitalize on early-stage seed funding history and modest revenue to attract grant opportunities and strategic investors, presenting as a high-risk, high-reward biotech with room for accelerated burn and milestones tied to platform validation.

Tech Differentiator Position the patented 2-for-1 CRISPR delivery mechanism as a scalable enabling technology for in vivo gene therapy, pursuing partnerships with contract research organizations, CROs, and translational labs seeking novel delivery platforms.

Geographic and Ecosystem Fit Leverage Cambridge, MA proximity to top biotech clusters and universities to establish joint development programs, access local talent, and engage with potential academic-based co-development and licensing opportunities.